SPY304.24-0.08 -0.03%
DIA254.07-0.22 -0.09%
IXIC9,504.19+14.32 0.15%

Helix BioPharma To Present L-DOS47 Phase 1 Lung Cancer Trial Data At ASCO May 29-31

Helix BioPharma Corp. (TSX:HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, announces that topline data

Benzinga · 05/14/2020 11:33

Helix BioPharma Corp. (TSX:HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, announces that topline data of the recently completed L-DOS47 dose escalation study in combination with pemetrexed and carboplatin in recurrent or metastatic non-squamous non-small cell lung cancer (“LDOS001”) will be published at the ASCO 2020 Annual Conference.

The ASCO publication details are:

Abstract: e21680

Title: Phase I dose escalation study of immunoconjugate L-DOS47 in combination with pemetrexed/carboplatin in non-squamous non-small cell lung cancer (“NSCLC”) patients.

Authors: Afshin Dowlati, Chandra Prakash Belani, George R. Simon, Heman Chao, Sarina Anne Piha-Paul; University Hospitals Case Medical Center, Cleveland, OH; Penn State Cancer Institute, Hershey, PA; Department of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX; Helix BioPharma Corp, Aurora, ON; Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX.

NCT Registration number: NCT02309892

Results: Fourteen (14) patients were enrolled across 6 dosing cohorts in the study.  No dose limiting toxicities were observed.  Of the twelve (12) patients evaluated for efficacy, 5 patients (41.7%) had a partial response (“PR”), 4 patients (33.3%) experienced stable disease (“SD”) and 3 patients (25.0%) had progressive disease (“PD”). The objective response rate is 41.7%. The clinical benefit rate is 75.0%.  L-DOS47, in combination with pemetrexed/carboplatin, appears to be well tolerated with promising anti-tumor activity against non-squamous NSCLC.

“I would like to thank the patients and their families who participated in our clinical study, as well as the principle investigators and associates who helped conduct the study,” said Dr. Heman Chao, Helix’s Chief Executive Officer.  “We are very optimistic with L-DOS47’s demonstrated excellent safety profile and encouraging efficacy data.”